AMicale des COXiens

Forum des actionnaires particuliers de NicOx
 
AccueilAccueil  GalerieGalerie  S'enregistrerS'enregistrer  ConnexionConnexion  

Partagez | 
 

 biotechnology perspectives

Voir le sujet précédent Voir le sujet suivant Aller en bas 
AuteurMessage
vinsse

avatar

Nombre de messages : 515
Date d'inscription : 15/05/2008

MessageSujet: biotechnology perspectives   Mar 11 Aoû - 22:23

http://www.saworldview.com/

tlc le pdf en haut et à droite ,pour nicox c'est page 5 et 6
Fighting in the Face of Distress



Undervalued and cash-strapped, a global industry wrestles with its future



by
Mike May






Along
the Mediterranean coast of France, people are concerned with more than
films. Just 20 minutes to the north of Cannes lies Sophia Antipolis—a
technology park with clients ranging from Agilent Technologies to W3C,
the World Wide Web Consortium. This is also home to NicOx, a company
focused on producing drugs from compounds that release the well-known
signaling molecule nitric oxide. NicOx is alive today only because of
its failures in the past. In short, NicOx once focused on ideas
more than products. “That was almost killing us,” says Michele Garufi,
chairman and chief executive officer of NicOx. Like many small
companies in biotech, NicOx once operated as if it existed in an
academic environment rather than a commercial one. “In 2003, we said:
‘It’s time to be concrete, because we have no money, and we must invest
every penny in a product that becomes a reality, rather than merely a
hope.’” That transition turned NicOx toward pushing ahead naproxcinod,
its anti-inflammatory compound under development for treating the signs
and symptoms of osteoarthritis. By concentrating on producing a
product it took just five years for NicOx to get naproxcinod through
Phase III trials, which showed that this drug is effective and safe.
Consequently NicOx expects to file a new drug application in 2009. As
Garufi points out: “It’s very important for a biotech company to get
something on the market even if it is a niche indication in a small
market.” If naproxcinod does get to market, though, it will be far
beyond a niche. It will be gigantic. Garufi estimates the market as a
“possible billion dollars a year in the U.S.” So it is possible
to face failure and then fight back toward success. While today’s
economic environment makes many biotechnology companies around the
world struggle, a range of experts envision success even during a down
economy. Assessing the Environment

"Our companies take
10 to 15 years to take a product from bench to bedside,” notes Alan
Eisenberg, executive vice president for the Biotechnology Industry
Organization’s emerging company section. “During that time there is
preclinical testing and testing that goes on in humans—first for
safety, then efficacy and finally larger-scale population testing. That
length of time and complexity represents high levels of risk from a
financial standpoint." That risk, though, is not entirely new. In fact,
biotechnology in the United States started feeling the crunch in 2007.
“We entered a credit crisis beginning in August 2007,” Eisenberg says,
“and that became a capital crisis.” As a result, investors started
looking for lower-risk opportunities in 2008. That creates problems for
companies developing new therapeutics, a high-cost enterprise. As
Eisenberg explains: “Projects get delayed, and some get shelved,
because companies can’t raise capital.” A similar divide exists
in Europe. “Most companies in Europe with products on the market are
selling medical products that are not immediately affected by the
economic downturn,” says Willy De Greef, secretary general for
EuropaBio, “but start-ups or companies working on their pipeline that
don’t have a current cash flow are in for some very difficult times.”
(See sidebar “Europe’s No Silicon Valley.”) For a brand new
start-up in Europe, De Greef declares, “I wouldn’t want to be the
manager looking for money this year.” On the other hand, if a company
finished a round of raising capital in 2008, De Greef thinks that it
should survive, as long as the company has enough money for a couple of
years. “CFOs who have turned down all of the unneccessaries and use
their money sparingly will probably do okay-ish,” De Greef says. Beyond
the challenges faced by start-ups, some experts see today’s financial
trouble crippling mid-stage companies. “A company that is just getting
back Phase II data or starting a Phase III trial often need tens of
millions of dollars,” according to Spencer Feldman, an attorney with
Greenberg Traurig in New York city and an expert on providing counsel
to emerging biotechnology companies. “That is difficult to get right
now.” Feldman adds that large pharmaceutical companies often use this
situation to their advantage. He continues: “These mid-size companies
are left abandoned, giving big pharma the opportunity to come in and
buy the valuable IP in bankruptcy or in a distressed selling situation.”
un autre lien
http://formularyjournal.modernmedicine.com/drug+watch

avec naproxcinod


Dernière édition par vinsse le Sam 29 Aoû - 22:36, édité 2 fois
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
vinsse

avatar

Nombre de messages : 515
Date d'inscription : 15/05/2008

MessageSujet: marketing scientifique   Mar 11 Aoû - 22:42



29 Aug 200912:00-13:30 Emerging
therapeutic strategies for the treatment of osteoarthritis (OA)
patients with hypertension: the physiologic and pharmacologic effects
of nitric oxide.
Chairperson(s) : T F Luescher (Zurich, CH), P Verdecchia (Perugia, IT)Prague - Zone 6
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
JeanCox

avatar

Nombre de messages : 1008
Age : 63
Date d'inscription : 19/12/2007

MessageSujet: Re: biotechnology perspectives   Mer 12 Aoû - 8:21

vinsse a écrit:
http://www.saworldview.com/

tlc le pdf en haut et à droite ,pour nicox c'est page 5 et 6

Merci beaucoup Vinsse, je ne connaissais pas Scientific American et leur revue qui est fort intéressante !
Quel est leur rythme de parution ? Mensuel ?

Je viens de mettre le lien en favoris Very Happy
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
Invité
Invité



MessageSujet: Re: biotechnology perspectives   Mer 12 Aoû - 9:13

merci Vinsse !
Revenir en haut Aller en bas
D@n (Daniel Beldio)

avatar

Nombre de messages : 3210
Age : 65
Localisation : Pays de l'Arbre et de l'Eau
Date d'inscription : 09/02/2007

MessageSujet: Re: biotechnology perspectives   Jeu 13 Aoû - 9:56

Merci Vincent ! Wink
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
vinsse

avatar

Nombre de messages : 515
Date d'inscription : 15/05/2008

MessageSujet: Re: biotechnology perspectives   Dim 16 Aoû - 12:15



7/10 octobre 2009


12:15pm – 1:45pm
Lunch SymposiumClinical Dilemmas in Managing the Hypertensive Patient with Osteoarthritis
Michael Farkouh, MD; Alan Gradman, MD; R. Preston Mason, PhD; William White, MD
Supported by an educational grant from NicOx, Inc.
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
D@n (Daniel Beldio)

avatar

Nombre de messages : 3210
Age : 65
Localisation : Pays de l'Arbre et de l'Eau
Date d'inscription : 09/02/2007

MessageSujet: Re: biotechnology perspectives   Lun 17 Aoû - 0:31

Revenir en haut Aller en bas
Voir le profil de l'utilisateur
vinsse

avatar

Nombre de messages : 515
Date d'inscription : 15/05/2008

MessageSujet: encore.....+ un stand prés d'amgen   Lun 17 Aoû - 15:06

ACKNOWLEDGMENTS


The following companies have made contributions in support
of Assembly CME events. Most of these Assembly event
supporters are also exhibitors.
These companies are corporate sponsors
of the AAFP Foundation.
Allergan
Satellite CME Event
AstraZeneca
Satellite CME Event, 60-minute seminar
Boehringer Ingelheim Pharmaceuticals, Inc.
Satellite CME Event
Daiichi Sankyo, Inc./Eli Lilly and Company
Satellite CME Event
Eli Lilly and Company
Satellite CME Event
GlaxoSmithKline
60-minute seminar
Merck & Co., Inc.
60-minute seminar (2)
Novo Nordisk Inc.
Satellite CME Event
Pharmavite LLC
60-minute seminar
sanofi pasteur
60-minute seminar
Takeda Pharmaceuticals North America, Inc.
Satellite CME Event
3Gen
Clinical Procedures Workshops/In-kind Support
Audio-Digest Foundation
CME Educational Grant
Brymill
Clinical Procedures Workshops/In-kind Support
CONMED
Clinical Procedures Workshops/In-kind Support
CryoPen, Inc.
Clinical Procedures Workshops/In-kind Support
Ellman International Inc.
Clinical Procedures Workshops/In-kind Support
The Leukemia & Lymphoma Society
Satellite CME Event
Medtronic, Inc.
60-minute seminar
NiCox
Satellite CME Event

Nutricia North America
Satellite CME Event
The following companies have made contributions in support
of Assembly non-CME events. Most of these Assembly event
supporters are also exhibitors.
These companies are corporate sponsors
of the AAFP Foundation.
Allergan
Satellite Event Map
Amgen
Product Theater, Lanyards
Boehringer Ingelheim Pharmaceuticals, Inc.
Product Theaters (2)
Bristol Myers Squibb / AstraZeneca
Product Theater
Eli Lilly and Company
Product Theater
Forest Laboratories, Inc.
Product Theater
Merck & Co., Inc.
Product Theater, UpClose Assembly Edition
Novartis Pharmaceuticals Corporation
Banner
Novo Nordisk Inc.
5K Family Fun Run/Walk, On the Floor Live, Banner
Pfizer Inc
Product Theater
Purdue Pharma LP
PDA Guide, Product Theater
sanofi pasteur
On the Floor Live
Welch Allyn
International Networking Meeting/PWH Reception
The Dannon Company
UpClose Assembly Edition
Merck Vaccine Division
Product Theater, On the Floor Preview, On the Floor Live
PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Product Theaters (2)
Primary Care Education Group
Satellite Event Map
UpToDate



October 14 – 17, 2009
|
BOSTON


www.aafp.org/assembly09

Revenir en haut Aller en bas
Voir le profil de l'utilisateur
Contenu sponsorisé




MessageSujet: Re: biotechnology perspectives   

Revenir en haut Aller en bas
 
biotechnology perspectives
Voir le sujet précédent Voir le sujet suivant Revenir en haut 
Page 1 sur 1
 Sujets similaires
-
» Perspectives Prix de l'Or / Peak Gold, etc
» Réfutation des prévisions cours argent métal 2011 de Cabalasmédias by J.Hommel
» Fed , or et $ , historique et perspectives
» Perspectives d'évolution de la flotte mondiale
» Les perspectives des loueurs pour 2010 et au delà

Permission de ce forum:Vous ne pouvez pas répondre aux sujets dans ce forum
AMicale des COXiens :: Forum public :: Echanges sur NicOx-
Sauter vers: